Last 46 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -4.40 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 9999.00 | 29.56 | 41.66 | 19.20 | 23.68 | 24.78 | 21.33 | 17.55 | 13.80 | 15.99 | 11.48 | 21.15 | 25.66 |
| — | +19.3% | +95.4% | +9.4% | +71.5% | +55.0% | +85.8% | -17.0% | -46.2% | -47.8% | -72.1% | -39.6% | -15.0% | |
| P/B Ratio | 6.34 | 2.85 | 4.02 | 2.53 | 3.12 | 6.32 | 5.44 | 1.74 | 2.07 | 1.82 | 1.06 | 3.73 | 2.82 |
| — | -54.8% | -26.0% | +45.1% | +50.9% | +246.4% | +413.1% | -53.2% | -26.7% | -27.9% | -62.2% | +87.6% | -13.2% | |
| P/FCF | — | — | — | — | — | — | — | — | — | 33.00 | — | 15.84 | — |
| — | — | — | — | — | — | — | — | — | -28.8% | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Can-Fite BioPharma Ltd.'s operating margin was -2424.8% in Q2 2025, down 0.0 pp QoQ and down 1129.2 pp YoY. The trailing four-quarter average of -1776.1% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind.
| Metric | TTM | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| — | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Margin | -1206.2% | -2424.8% | -2424.8% | -1127.4% | -1127.4% | -1295.6% | -1295.6% | -1183.2% | -951.5% | -910.2% | -1383.7% | -1565.0% | -1261.3% |
| — | -87.2% | -87.2% | +4.7% | -18.5% | -42.3% | +6.4% | +24.4% | +24.6% | +10.3% | -19.7% | +20.7% | +9.8% | |
| Net Margin | -1169.1% | -2413.9% | -2413.9% | -1095.5% | -1095.5% | -1251.9% | -1251.9% | -1065.8% | -899.0% | -852.0% | -1218.4% | -1500.0% | -1196.6% |
| — | -92.8% | -92.8% | -2.8% | -21.9% | -46.9% | -2.8% | +28.9% | +24.9% | +28.6% | +2.5% | +25.7% | +11.7% |
| Metric | TTM | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -134.9% | -58.3% | -50.7% | -36.1% | -49.6% | -79.8% | -45.4% | -28.8% | -29.1% | -21.7% | -36.8% | -49.7% | -28.2% |
| — | +27.0% | -11.8% | -25.3% | -70.3% | -267.1% | -23.1% | +42.0% | -3.2% | +2.1% | -89.8% | -43.0% | +44.9% | |
| ROA | -82.5% | -31.6% | -29.0% | -21.5% | -26.1% | -33.4% | -24.9% | -17.2% | -17.4% | -13.6% | -21.0% | -26.9% | -17.8% |
| — | +5.5% | -16.5% | -24.7% | -49.5% | -145.2% | -18.5% | +35.8% | +1.9% | +8.8% | -55.9% | -13.9% | +36.4% | |
| ROIC | -448.3% | — | — | -211.7% | — | — | — | -70.4% | -51.9% | -24.9% | -46.1% | -86.7% | -32.1% |
| — | — | — | -200.7% | — | — | — | +18.9% | -62.1% | -19.3% | -116.9% | -97.4% | +59.7% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has improved 22.6% YoY to 3.60x, strengthening the short-term liquidity position.
| Metric | TTM | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| — | -6.4% | -6.4% | +198.6% | +96.4% | +139.5% | +306.8% | -53.8% | -2.2% | +9.2% | -37.7% | +60.8% | -8.8% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 4.38 | 3.60 | 3.60 | 4.38 | 4.38 | 2.93 | 2.93 | 4.90 | 4.10 | 4.89 | 4.63 | 3.66 | 4.49 |
| — | +22.6% | +22.6% | -10.8% | +6.7% | -40.0% | -36.6% | +34.0% | -8.7% | -27.9% | -24.0% | -50.2% | -33.2% | |
| Quick Ratio | 4.38 | 3.60 | 3.60 | 4.38 | 4.38 | 2.93 | 2.93 | 4.90 | 4.10 | 4.89 | 4.63 | 3.66 | 4.49 |
| — | +22.6% | +22.6% | -10.8% | +6.7% | -40.0% | -36.6% | +34.0% | -8.7% | -27.9% | -24.0% | -50.2% | -36.7% | |
| Interest Coverage | -580.71 | — | — | — | — | — | — | -131.00 | -621.67 | — | — | -192.69 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 46 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonCan-Fite BioPharma Ltd.'s current P/E is -4.4x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Can-Fite BioPharma Ltd.'s current operating margin is -1206.2%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Can-Fite BioPharma Ltd.'s business trajectory between earnings reports.